Akari Therapeutics Plcの発行済株式数
Akari Therapeutics Plcの発行済株式数は何ですか。
Akari Therapeutics Plcの発行済株式数は12.145Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
NASDAQのセクタHealth Careにおける発行済株式数の企業と比べるAkari Therapeutics Plc
Akari Therapeutics Plcは何をしますか。
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Akari Therapeutics Plcと類似の発行済株式数
- Credit Acceptanceの発行済株式数は12.111Mです。
- Stratec SEの発行済株式数は12.128Mです。
- Immunomeの発行済株式数は12.129Mです。
- Swaraj Enginesの発行済株式数は12.134Mです。
- Swaraj Enginesの発行済株式数は12.141Mです。
- Le Tanneur & Cie Societe anonymeの発行済株式数は12.144Mです。
- Akari Therapeutics Plcの発行済株式数は12.145Mです。
- S&U Plcの発行済株式数は12.151Mです。
- John Hancock Hedged equity & Income Fundの発行済株式数は12.151Mです。
- Gandhi Special Tubesの発行済株式数は12.152Mです。
- Emmis Corpの発行済株式数は12.157Mです。
- Prime People Plcの発行済株式数は12.157Mです。
- PermRock Royalty Trustの発行済株式数は12.166Mです。